Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7400521 | 0.84 | TSHR (0.54) | TSHRHTR1AHTR1DHTR2CKDM1A | |
| SCHEMBL3862277 | 0.84 | ALDH1A1 (0.50) | TSHRCA1CA2KDM4EALDH1A1 | |
| SCHEMBL11696154 | 0.82 | NPC1 (0.50) | NPC1RAB9ACA1CA2KDM4E | |
| SCHEMBL3642753 | 0.79 | TSHR (0.53) | TSHRHTR1AHTR1DHTR2CKDM1A | |
| SCHEMBL11696436 | 0.78 | ATM (0.55) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL11841323 | 0.78 | HDAC8 (0.42) | TSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11692745 | 0.78 | ALDH1A1 (0.55) | TSHRNPC1RAB9ASMN1; SMN2CA1 | |
| SCHEMBL11693909 | 0.78 | KDM4E (0.46) | TSHRNPC1RAB9ACASP3SMN1; SMN2 | |
| Benzamide SCHEMBL1395144 | 0.76 | PARP1 (0.53) | TSHRNPC1RAB9ACASP3SMN1; SMN2 | |
| SCHEMBL7434437 | 0.76 | TSHR (0.49) | TSHRHTR1AHTR1DHTR2CKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974856-A | Preparation method of medicine of vatistal for treating adult T cell leukemia lymphoma | 北京康立生医药技术开发有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-110191722-A | Pharmaceutical composition for treating HTLV-1 related myelopathy | 第一三共株式会社 | 2019-08-30 | — | — | CN | claimed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| WO-2012014127-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-02-02 | — | — | WO | claimed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | claimed |
| WO-2023209591-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 AND/OR EZH2 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | WO | disclosed |
| US-11801209-B2 | Cooling and flavor boosting compositions | FIRMENICH SA (CH) | 2023-10-31 | — | — | US | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| CN-115974856-A | Preparation method of medicine of vatistal for treating adult T cell leukemia lymphoma | 北京康立生医药技术开发有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-11185100-B2 | Methods for modulating taste receptors | MARS, INCORPORATED (US) | 2021-11-30 | — | — | US | disclosed |
| CN-108699041-B | Imidazole derivative having JNK inhibitory activity and use thereof | 三进制药株式会社 | 2021-03-26 | — | — | CN | disclosed |
| US-20200306156-A1 | COOLING AND FLAVOR BOOSTING COMPOSITIONS | FIRMENICH SA (CH) | 2020-10-01 | — | — | US | disclosed |
| US-20180255813-A1 | METHODS FOR MODULATING TASTE RECEPTORS | MARS, INCORPORATED (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | SNAPDRAGON CHEMISTRY, INC. | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | TSHR 1548/4885HTR1A 2040/4885HTR1D 1255/4885 |
| US-20200306156-A1 | COOLING AND FLAVOR BOOSTING COMPOSITIONS | TAS2R20, TAS2R10, TAS2R40 | TSHR 3585/4885HTR1A 1998/4885HTR1D 2795/4885 |
| US-11801209-B2 | Cooling and flavor boosting compositions | TAS2R20, TAS2R10, TAS2R40 | TSHR 3585/4885HTR1A 1998/4885HTR1D 2795/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | TSHR 4775/4885HTR1A 4184/4885HTR1D 4102/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | TSHR 1548/4885HTR1A 2040/4885HTR1D 1255/4885 |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | SERPINB10, SERPINB8, SERPINE1 | TSHR 3173/4885HTR1A 4334/4885HTR1D 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.